EPR-effect: Utilizing size-dependent nanoparticle delivery to solid tumors

Therapeutic Delivery

Volumn 4, Issue 4, 2013, Pages 421-423

  Stylianopoulos, Triantafyllos ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

cancer; drug delivery; nanomedicine; tumor microenvironment

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; NANOPARTICLE; PACLITAXEL;

BREAST METASTASIS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRUG TRANSPORT; KAPOSI SARCOMA; KIDNEY CLEARANCE; NANOMEDICINE; OVARY METASTASIS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT;

EID: 84875962586     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.8     Document Type: Review

References (20)

1. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288-305 (1986
2. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986
3. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-64 (2010
4. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607-4612 (1998
5. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes. Res. 2, 14 (2010
6. O'Brien MER, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (Caelyx®/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15, 440-449 (2004
7. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005
8. Gill PS, Wernz J, Scadden DT et al. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related kaposi's sarcoma. J. Clin. Oncol. 14, 2353-2364 (1996
9. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies. Ann. Rev. Chem. Biomolecular Eng. 2, 281-298 (2011
10. Chauhan VP, Stylianopoulos T, Martin JD et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7, 383-388 (2012
11. Pluen A, Boucher Y, Ramanujan S et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc. Natl Acad. Sci USA 98, 4628-4633 (2001
12. Peracchia MT, Fattal E, Desmaele D et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 60, 121-128 (1999
13. Choi HS, Liu W, Misra P et al. Renal clearance of quantum dots. Nat. Biotechnol. 25, 1165-1170 (2007
14. Chauhan VP, Popovic Z, Chen O et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem. Int. Ed. Engl. 50, 11417-11420 (2011
15. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: Molecular charge dependence. Br. J. Cancer 82, 1513-1518 (2000
16. Stylianopoulos T, Soteriou K, Fukumura D, Jain RK. Cationic nanoparticles have superior transvascular flux into solid tumors: Insights from a mathematical model. Ann. Biomed. Eng. 41, 68-77 (2013
17. Kale AA, Torchilin VP. Environment-responsive multifunctional liposomes. Methods Mol. Biol. 605, 213-242 (2010
18. Wong C, Stylianopoulos T, Cui J et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. USA 108, 2426-2431 (2011
19. Sugahara KN, Teesalu T, Karmali PP et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031-1035 (2010
20. Davis ME, Zuckerman JE, Choi CHJ et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).